The United Sorghum Checkoff Program announced the launch of the first human clinical trial to evaluate whole grain sorghum’s health benefits. Funded by the Checkoff and conducted by the University of Nebraska-Lincoln, the landmark study will investigate how daily consumption of two whole-grain sorghum varieties – a traditional white sorghum and a “sumac” sorghum - influences key health markers such as insulin resistance, inflammation, and gut microbiome composition. “The first of its kind human study is a direct result of sorghum producers’ commitment to scientific research,” said Lanier Dabruzzi, director of nutrition and innovation with the Sorghum Checkoff. “By investing in rigorous clinical research, we aim to provide the science-backed evidence health professionals and food companies need to recognize sorghum as a truly beneficial grain for whole-body health.” Tim Lust, CEO of the Sorghum Checkoff, said farmers are proving how special sorghum is on the biggest stage, which is human nutrition.
Welcome
